Home » New Formulation of Multiple Sclerosis Treatment Rebif Approved in European Union
New Formulation of Multiple Sclerosis Treatment Rebif Approved in European Union
Merck Serono, a division of Merck KGaA, announced that the European Commission has granted a marketing authorization for a new formulation of Rebif (interferon beta-1a) for the treatment of relapsing multiple sclerosis (MS).
ITnews
Upcoming Events
-
07May
-
14May
-
30May